Overview
Adam W. Burrowbridge focuses his practice on complex intellectual property litigation in district court and the Federal Circuit. He counsels clients in the life science and technology sectors and covers a wide range of technologies, including pharmaceuticals, software, medical devices and consumer products. He has extensive experience representing both plaintiffs and defendants in all phases of litigation, from filing of suit through trial, appeal and practice at the US Supreme Court.
Adam previously clerked for the Honorable Pauline Newman at the US Court of Appeals for the Federal Circuit. Before his clerkship, he worked on international IP issues, including patent harmonization, in the Office of Policy and International Affairs at the US Patent and Trademark Office. Adam also worked at the White House in the Office of Science and Technology Policy, where he focused on technology transfer issues in support of the president’s Global Development Policy for Health, Climate Change and Food Security. He also represented the American Intellectual Property Law Association (AIPLA) as a delegate at the United Nations Framework Convention on Climate Change, COP 16.
Adam maintains an active pro bono practice. He has represented several underrepresented clients including veterans, refugees and impoverished persons that face access to justice challenges.
Results
- Secured a series of wins for United Therapeutics in patent infringement disputes filed under the Hatch-Waxman Act involving its Tyvaso product, including securing a win following trial in which the judge ruled Liquidia’s proposed 505(b)(2) product infringes one of United Therapeutics’ patents, which was subsequently affirmed by the Federal Circuit (United Therapeutics Corporation v. Liquidia Technologies, Inc.)
- Secured a Federal Circuit reversal of a patent term adjustment decision that cost his clients more than a year and a half of patent term relating to the oral pulmonary hypertension drug Orenitram, invalidating a US Patent and Trademark Office (USPTO) regulation that the Federal Circuit had previously affirmed as reasonable (Supernus et al. v. Iancu)*
- Secured a Federal Circuit affirmance invalidating two formulation patents relating to Sanofi’s blockbuster insulin glargine Lantus product (Mylan v. Sanofi-Aventis (PTO))*
- Obtained favorable dismissal of cell sorter patent litigation (Cytonome v. NanoCellect (D. Del.))*
- Obtained summary judgment of invalidity in generic-side Hatch-Waxman litigation relating to Pfizer’s blockbuster Celebrex product ( Searle et al. v. Lupin et al. (E.D. Va.))*
- Obtained summary affirmance of district court order enforcing oral settlement agreement resolving Frova litigation (Endo v. Mylan (D. Del.))*
*Matter handled prior to joining McDermott.
Recognitions
- Washington, DC Super Lawyers, Intellectual Property, 2019-present
- Best Lawyers: Ones to Watch in America, Litigation – Intellectual Property, Washington, DC, 2024-present
Community
- Federal Circuit Bar Association, member
- Giles Rich Inn of Court, member
- Washington Council of Lawyers, member
Credentials
Education
American University Washington College of Law, JD, 2011
James Madison University, BS, Integrated Science & Technology (Biotechnology), 2003
Admissions
District of Columbia
Virginia
Courts / Agencies
US Supreme Court
US Court of Appeals for the Federal Circuit
US Court of Appeals for the Sixth Circuit
US Court of Appeals for the Ninth Circuit
US Court of Appeals for the Eleventh Circuit
US Court of Appeals for Veterans Claims
